Dupuytrens Disease Therapeutics Market
According to Intent Market Research, the Dupuytrens Disease Therapeutics is expected to grow from USD 0.9 billion in 2023 at a CAGR of 17.4% to touch USD 2.8 billion by 2030. The Dupuytrens Disease Therapeutics is dominated by key players such as AbbVie Inc., Sanofi S.A., Pfizer Inc., Medytox Inc., Boehringer Ingelheim, Mylan N.V., Endo International PLC, Ipsen Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Grunenthal GmbH, Eli Lilly and Co., Haplo Therapeutics, Allergan PLC, Amgen Inc., Stryker Corporation.